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Pancreatic  cancer  is  a  very  aggressive  disease 
with dismal prognosis (Hidalgo, 2010). Desmo-
plasia/fibrosis, which is not present around nor-
mal pancreatic ducts, is a hallmark in pancreatic 
cancer and it is believed to play an active role in 
disease  progression  and  aggressiveness  (Kleeff   
et al., 2007; Mahadevan and Von Hoff, 2007). 
Tumor stroma is predominantly infiltrated by 
Th2 (GATA-3+) over Th1 (T-bet+) cells (Tassi 
et al., 2008). This immune infiltrate correlates 
with the presence in the blood of pancreatic 
cancer patients of tumor-specific CD4+ T cells 
producing mostly IL-5 and IL-13 (Tassi et al., 
2008). Th2 cytokines and IL-13 in particular are 
strongly linked to fibrogenesis (Wynn, 2004).
Open questions are what leads to the Th2 im-
mune deviation in pancreatic cancer and whether 
Th2 cells present at the tumor site have a role in 
disease progression. We hypothesized that tumor-
resident DCs are conditioned by factors released 
by tumor cells or tumor stroma to favor, in the 
draining  LNs,  differentiation  of  tumor-specific 
Th2 cells, which then home to the tumor and 
possibly contribute to disease progression by inter-
acting with other immune and nonimmune cells 
(Joyce and Pollard, 2009) and, through Th2 cyto-
kines secretion, to fibrosis (Wynn, 2004).
The thymic stromal lymphopoietin (TSLP; 
i.e., an IL-7–like cytokine) has been recently 
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Pancreatic cancer is a very aggressive disease characterized by a marked desmoplasia with a 
predominant Th2 (GATA-3+) over Th1 (T-bet+) lymphoid infiltrate. We found that the ratio 
of GATA-3+/T-bet+ tumor-infiltrating lymphoid cells is an independent predictive marker of 
patient survival. Patients surgically treated for stage IB/III disease with a ratio inferior to 
the median value had a statistically significant prolonged overall survival, implying an 
active role for Th2 responses in disease progression. Thymic stromal lymphopoietin (TSLP), 
which favors Th2 cell polarization through myeloid dendritic cell (DC) conditioning, was 
secreted by cancer-associated fibroblasts (CAFs) after activation with tumor-derived tumor 
necrosis factor  and interleukin 1. TSLP-containing supernatants from activated CAFs 
induced in vitro myeloid DCs to up-regulate the TSLP receptor (TSLPR), secrete Th2- 
attracting chemokines, and acquire TSLP-dependent Th2-polarizing capability in vitro.  
In vivo, Th2 chemoattractants were expressed in the tumor and in the stroma, and TSLPR-
expressing DCs were present in the tumor stroma and in tumor-draining but not in nond-
raining lymph nodes. Collectively, this study identifies in pancreatic cancer a cross talk 
between tumor cells and CAFs, resulting in a TSLP-dependent induction of Th2-type in-
flammation which associates with reduced patient survival. Thus, blocking TSLP production 
by CAFs might help to improve prognosis in pancreatic cancer.
© 2011 De Monte et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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Th2 cells varied among the samples (Fig. 1 B). To verify pos-
sible quantitative differences among samples, we then calcu-
lated the G/T ratio for each patient (Fig. 1 C). Indeed, Cox 
regression model showed no significant correlation between 
overall survival and the absolute number of either GATA-3+ 
(hazard ratio = 1.00; 95% confidence interval [CI] 1.00–1.00; 
P = 0.73) or T-bet+ (hazard ratio = 1.00; 95% CI 1.00–1.00; 
P = 0.52) cells. Conversely, a significant correlation between 
G/T ratio and overall survival was detected (hazard ratio =   
1.04; 95% CI 1.01–1.04; P = 0.038). The median value of   
G/T ratio was 5.2; 35 patients had a G/T ratio ≤ 5.2 (group A)   
and 34 patients had a G/T ratio > 5.2 (group B; patient 
characteristics grouped by the G/T ratio are reported in   
Table I). After a median followup of 41 mo (range 22–134), 
58 patients had recurrence and 53 died from the disease. Me-
dian 1-yr and 2-yr disease-free survival was 15.2 mo, 71 and 
43% for group A, and 11.0 mo, 47 and 18% for group B (P = 
0.02). Median 2-yr and 3-yr overall survival was 32.7 mo, 66 
and 45% for group A, and 20.2 mo, 44 and 26% in group B   
(P = 0.008; Fig. 1 D and Fig. S1). Multivariate analysis strati-
fying for tumor stage, grading, size, site, patient performance 
status, gender, age, surgical resection margins, postoperative 
CA19.9 value, and postoperative treatment confirmed that the 
G/T ratio was independently predictive of both disease-free 
survival (P = 0.002, hazard ratio = 1.06, 95% CI 1.03–1.10) 
and overall survival (P = 0.005, hazard ratio = 1.06, 95% CI 
1.02–1.09). Hence, the GATA-3+ cells present in the tumor 
stroma associate with disease progression, and we identified a 
parameter (i.e., the G/T ratio) that is independently predic-
tive of patients’ survival.
TSLP is produced by cancer-associated fibroblasts (CAFs) 
after activation by tumor-derived TNF and IL-1
To  investigate  the  potential  role  of 
TSLP in driving Th2 immune deviation 
associated with induction of Th2 responses through DC acti-
vation (Liu et al., 2007). Hence, in this paper we evaluated, 
first, the prognostic significance of Th2-infiltrating lymphoid 
cells in surgical specimens of patients who had resection of 
stage IB/III pancreatic cancer and, second, the potential im-
plication of TSLP in inducing the Th2 immune deviation 
present in pancreatic cancer.
RESULTS
The ratio of GATA-3+/T-bet+ (G/T) tumor-infiltrating 
lymphoid cells predicts survival after surgery in patients 
with stage IB/III pancreatic cancer
To determine the possible association between Th2 cells and 
disease progression, we enumerated by immunohistochemis-
try the GATA-3+ and T-bet+ lymphoid cell–infiltrating tumor 
samples from 69 patients who underwent surgical resection 
(Fig. 1 A, left). GATA-3 was also expressed in the cytoplasm 
of epithelial cells as already shown in Tassi et al. (2008; Fig. 1 A, 
top). Lymphoid cell infiltrate was mostly present exclusively 
in the tumor stroma and varied among samples. Pancreatic 
tissue from surgical samples of patients who underwent sur-
gery for benign lesions is also shown as normal control. Com-
pared with the tumor, in which the stromal component is 
very represented, normal pancreatic tissue is composed by a 
compact acinar structure that contains rare and equal num-
bers of lymphoid cells positive for GATA-3 and T-bet (Fig. 1 A, 
right). Because the amount of lymphoid cells in the tumor 
varied among samples, we then calculated for each patient 
the percentage of positive lymphoid cells and found that in 
all but one sample the percentage of GATA-3+ cells was sig-
nificantly higher than that of T-bet+ (Fig. 1 B), demonstrating 
that Th2 immune deviation in pancreatic cancer is a gener-
alized phenomenon. However, the percentage of intratumor 
Figure 1.  The ratio of G/T tumor- 
infiltrating lymphoid cells predicts survival 
after surgery in patients with stage IB/III 
pancreatic cancer. (A) Representative immuno-
histochemical analysis for lymphoid  
GATA-3 and T-bet staining in the tumor (n = 69; 
left) and normal pancreatic tissue from  
benign lesions (n = 3; right). The arrows indi-
cate rare positive cells in normal tissue. Bars, 
100 µm. (B) Percentage of GATA-3+ (circles) 
and T-bet+ (triangles) lymphoid cells for each 
of the analyzed tumor samples (n = 69). The 
values are significantly different and indicated 
as: ***, P < 0.001 (determined by paired one-
tailed Student’s t test). (C) Waterfall plot of 
the G/T ratio for each tumor sample. The 
dashed line indicates the G/T ratio 5.2, which 
is the median value. (D) Kaplan-Meier curve 
for overall survival by median G/T ratio (5.2). 
Survival significantly decreased (P = 0.008) as 
a function of a G/T ratio ≥ 5.2.JEM VOL. 208, March 14, 2011 
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of TSLP (Fig. 2 A) and proinflammatory cytokines (Fig. 2 D) 
in the surrounding tissue is possibly related to its morpholog-
ical  characteristics  that  could  vary  among  samples  from 
conserved normal parenchyma to preexisting or associated 
obstructive pancreatitis.
To identify cells producing the proinflammatory cyto-
kines, we tested their expression in tumor epithelial and stro-
mal cells collected by LCM and in cultured paired tumor cells 
and CAFs from the same patient (Fig. 2 E). TNF was mainly 
expressed in tumor epithelial cells, compared with stroma 
cells, and not in CAFs (Fig. 2 E, left). IL-1 was expressed in 
both  tumor  compartments  and,  although  at  low  levels,  in 
CAFs (Fig. 2 E, right and inset). IL-1 secretion was con-
firmed by immunohistochemistry (unpublished data). As the 
two proinflammatory cytokines were expressed in tumor 
cells, we further tested whether treatment of CAFs with   
tumor cell supernatant induced TSLP secretion. CAFs, but 
not HDFs, treated with the tumor cell supernatant produced 
TSLP that was significantly inhibited by anti-TNF (34% in-
hibition) and anti–IL-1 (38% inhibition) Abs but not by an 
isotype  control  (Fig.  2  F).  Collectively,  these  experiments 
demonstrate that TSLP expression is up-regulated in pancre-
atic cancer and released by CAFs under the influence of 
TNF and IL-1 that are expressed in pancreatic cancer and 
secreted by tumor cells.
Myeloid DCs are activated by the supernatant  
of proinflammatory cytokine-treated CAFs and acquire  
Th2-polarizing capability
We next evaluated, in vitro, the effects of the supernatant of 
activated CAFs on myeloid DC maturation and function 
(Fig. 3). DCs conditioned by CAF supernatant strongly up-
regulated activation and maturation markers at levels compa-
rable to or even higher than those of TSLP and Poly I:C (i.e., 
controls for DCs maturation; Fig. 3 A).
The potential role of CAF-released TSLP in DC activation/
maturation was then investigated by looking at the expression of 
in pancreatic cancer, we evaluated, by real-time PCR, TSLP 
mRNA expression in tumor and macroscopically uninvolved 
surrounding tissues from surgical specimens, and in isolated 
and in vitro–cultured tumor cells and CAFs, as described in 
Materials and methods. CAF cell lines were obtained from 
surgical samples of 15 patients, and corresponding tumor cell 
lines from the same patients were obtained in five cases. Because 
normal human pancreatic fibroblasts were not available, human 
dermal fibroblasts (HDFs) from normal skin were used as 
control. All cell lines were tested after few passages in culture 
and their characterization is reported in Fig. S2. Although   
tumor  cell  lines,  when  established,  could  then  be  kept  in 
long-term culture as stabilized lines, usually CAFs could not 
grow longer than nine passages. We found that TSLP was ex-
pressed in the tumor and, to a much lower extent, in the sur-
rounding tissue (Fig. 2 A). Moreover, TSLP was expressed in 
CAFs but not in tumor cells and HDFs (Fig. 2 A). Expression 
of TSLP in the stroma, and not in tumor epithelial cells, was 
confirmed by laser capture microdissection (LCM; Fig. 2 B).
We then measured, by ELISA, TSLP secretion by CAFs 
after activation with proinflammatory cytokines known to 
induce TSLP production in epithelial cells (Lee and Ziegler, 
2007), smooth muscle cells (Zhang et al., 2007), and skin   
keratinocytes (Bogiatzi et al., 2007). TSLP secretion, in the 
absence of activation, was observed in a limited number of 
CAFs and never in tumor cells and HDFs (unpublished data). 
TNF  and  IL-1  used  as  single  agents  or  in  combination 
strongly increased or induced a significantly higher TSLP se-
cretion in CAFs than in HDFs. However, in agreement with 
the mRNA expression data, no TSLP production by tumor 
cells was observed (Fig. 2 C).
We then confirmed the presence of the proinflammatory 
cytokines in tumor samples (Fig. 2 D). TNF was expressed in 
the tumor at higher levels than in the corresponding sur-
rounding tissue (Fig. 2 D, top), whereas IL-1 was expressed 
in both tissues with prevalence in one or the other depending 
on the sample (Fig. 2 D, bottom). The variability of expression 
Table I.  Characteristics of the 69 patients grouped by the G/T ratio of tumor-infiltrating lymphoid cells
Variable G/T ≤ 5.2 (n = 35) G/T > 5.2 (n = 34)
Gender: female 18 (51%) 15 (44%)
Median age 64 57.5
Tumor site: head 31 (89%) 30 (88%)
Tumor size > 3 cm 9 (25%) 15 (44%)
Stage IIB/III 26 (74%) 31 (91%)
Grade 3 11 (31%) 12 (35%)
Karnofsky >80 24 (69%) 21 (62%)
Surgical margin R1 12 (34%) 15 (44%)
Median preoperative CA19.9 217 ± 3453.8 range (1–18,470) 94 ± 1342.6 range (1–6,832)
Median postoperative CA19.9 16 ± 88.8 range (1–416) 23 ± 678.6 range (0.1–3,745)
aTreatment: PEFG 18 (51%) 20 (59%)
aPatients who had R0 or R1 resection of a stage IB-III pancreatic cancer, aged 18–75 yr and Karnofsky Performance Status (KPS) > 60, were eligible for adjuvant therapy. The 
patients were required to have postoperative treatment initiation within 2 mo from surgery, no previous chemotherapy or radiotherapy for pancreatic cancer, and adequate 
bone marrow, liver, and kidney. After tumor resection, 31 patients were treated with gemcitabine (Burris et al., 1997) and 38 patients received the PEFG regimen consisting of 
cisplatin, epirubicin, gemcitabine, and 5-fluorouracil (Reni et al., 2005). In both cases, chemotherapy was administered for 3 mo followed by chemoradiation (Reni et al., 2005).472 TSLP-driven Th2 polarization in pancreatic cancer | De Monte et al.
Figure 2.  TSLP is expressed by CAFs, and its secretion is induced by proinflammatory cytokines released by tumor cells. (A) TSLP mRNA ex-
pression in tumor and surrounding tissues, tumor cell lines, CAFs, and HDFs. Each dot represents a different surgical sample or a different cell line.  
(B) TSLP is expressed in vivo in the stroma. LCM (left) was used to collect stromal (top) and epithelial (bottom) tumor cells from surgical specimens and 
TSLP mRNA expression analyzed (right; representative of tumor samples from three patients). The mRNA expression levels were normalized to the expres-
sion of GAPDH. TSLP mRNA expression of Caco2 cell line was used as calibrator, as in Rimoldi et al. (2005). (C) TSLP protein secretion by CAFs, HDFs, and 
tumor cell lines treated with proinflammatory cytokines as single agent or in combination. Left, 20 ng/ml TNF; middle, 10 ng/ml IL-1; right, TNF plus  
IL-1. Each dot represents a different cell line. (D) TNF (top) and IL-1 (bottom) mRNA expression in tumor and the corresponding surrounding tissue 
(each dot and corresponding triangle represent surgical samples from single patients). (E) TNF (left) and IL-1 (right) mRNA expression in tumor epithelial 
and stromal cells collected by LCM (top; representative of tumor samples from three patients) and in isolated and in vitro–cultured paired tumor cell lines 
and CAFs from the same patient (bottom; representative of tumor samples from three patients). Inset magnifies IL-1 expression in CAFs. (F) TSLP protein 
secretion by CAFs treated with supernatant from tumor cell lines (tumor cells sup) in the absence and presence of anti-TNF, anti–IL-1, and isotype con-
trol Abs (representative of experiments performed with three different tumor cell lines and three CAFs). Data in A–F are means of at least duplicate deter-
minations ± SD. Responses significantly different in A, C, D, and F are indicated as: *, P < 0.05; **, 0.001< P < 0.01 (determined by paired or unpaired 
one-tailed Student’s t test).JEM VOL. 208, March 14, 2011 
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thymus and activation-regulated chemokine (TARC/CCL17) 
and macrophage-derived chemokine (MDC/CCL22) were 
secreted as expected by TSLP-treated DCs and, importantly, 
by DCs conditioned with the supernatant of activated CAFs. 
In contrast, DCs conditioned with the supernatant of acti-
vated HDFs secreted MDC/CCL22 but not TARC/CCL17 
(Fig.  3  D). Th1  chemoattractants  RANTES/CCL5  and   
IP-10/CXCL10 were secreted exclusively by DCs conditioned 
with the HDF supernatant (Fig. 3 D).
To test their polarizing capability, DCs conditioned with 
the supernatant of TNF-treated CAFs were co-cultured with 
naive CD4+CD45RA+ T cells, purified from cord blood, in 
the absence or in the presence of neutralizing Abs. After 6 d, 
release of IFN- and IL-13 (as prototypic Th1 and Th2 cyto-
kines, respectively) by activated CD4+ T cells was assessed by 
ELISA (Fig. 3 E). TSLP-treated DCs, used as positive control, 
induced IL-13 as expected but not IFN-–producing CD4+ 
T cells. Notably, DCs conditioned with CAF supernatant also 
induced secretion of IL-13 that was inhibited by an anti-TSLP 
(47% inhibition) but not an anti-TNF Ab. CD4+  
T cells activated with DCs cultured with medium alone 
or TNF or the supernatant of TNF-treated HDFs re-
mained unpolarized (Fig. 3 E). Collectively, these data 
demonstrate that CAFs, via the release of TSLP, in-
duce DCs with features of TSLP-treated DCs.
the TSLP receptor (TSLPR), which is up-regulated in TSLP-
treated DCs (Soumelis et al., 2002; Ito et al., 2005; Lu et al., 
2009). We found that DCs treated with CAF supernatant ex-
pressed the TSPLR at higher levels than those treated with 
HDF supernatant (Fig. 3 B), indicating that a maturation 
stimulus for DC activation present in the CAF supernatant is 
TSLP. We further demonstrated that TSLP present in the su-
pernatant was responsible for DC activation by experiments 
in which CD80 expression, whose up-regulation is particularly 
influenced by TSLP (Soumelis et al., 2002; Bogiatzi et al., 2007), 
was inhibited by the addition of an anti-TSLP Ab (Fig. 3 C).
We then measured the secretion of cytokines and chemo-
kines by DCs either left untreated or treated with the super-
natants of TNF-treated CAFs and HDFs. TNF and TSLP were 
used as controls. After 24 h, DCs were extensively washed to 
remove any exogenous or fibroblast-produced cytokine and 
left for a further 48 h in culture before collecting the super-
natant. IL-12, IL-10, TNF, IL-1, and IL-6 were not produced 
in any condition (unpublished data). The Th2 chemoattractants 
Figure 3.  Supernatant of TNF-treated CAF (CAF sup)  
activates in vitro myeloid DCs with features of TSLP-treated 
DCs. (A) FACS analysis of DCs after 24-h incubation with the 
indicated stimuli (representative of independent experiments,  
n = 3). Experiments were performed with supernatants from 
three different CAFs. Open histograms represent staining of DC 
activation markers; filled histograms represent the isotype control.   
(B) FACS analysis of TSLPR expression by DCs activated in the 
presence of medium plus TNF, supernatant of TNF-treated HDF 
(HDF sup; obtained from two different HDFs), and CAF sup (ob-
tained from three different CAFs; representative of independent 
experiments n = 3). (C) FACS analysis of CD80 expression by DCs 
incubated with CAF sup (obtained from three different CAFs) in 
the absence and in the presence of an anti-TSLP Ab (representa-
tive of independent experiments, n = 4). Experiments with me-
dium plus TNF and TSLP, in the absence and in the presence of 
the anti-TSLP Ab, are shown as negative and positive controls, 
respectively. (D) Chemokine production by DCs activated with 
the following stimuli: medium alone, 20 ng/ml TNF; 15 ng/ml 
TSLP; HDF sup and CAF sup (representative of three experiments 
performed with three different CAFs and two different HDFs).  
(E) CAF sup endows DCs with Th2 polarizing capability that de-
pends on TSLP. CD4+CD45RA+ naive T cells were cultured with 
DCs previously activated with the indicated stimuli. At day 6, 
IFN- and IL-13 secreted by CD4+ T cells were tested by ELISA. 
When indicated, anti-TSLP and anti-TNF Abs were added in cul-
ture. Data are means of duplicate determinations ± SD and rep-
resent one of five experiments (performed with four different 
CAFs and two different HDFs). Release of IL-13 significantly 
lower in the presence of an anti-TSLP Ab are indicated as:  
*, P < 0.05; **, 0.001 < P < 0.01 (determined by unpaired one-
tailed Student’s t test).474 TSLP-driven Th2 polarization in pancreatic cancer | De Monte et al.
DCs with features of TSLP-treated DCs and Th2-attracting 
chemokines are present in vivo in pancreatic cancer patients
Finally, we investigated, by immunohistochemistry and flow 
cytometry, the presence in vivo of TSLP-conditioned DCs, 
identified  as  CD11c+TSLPR+  cells.  Myeloid  DCs  in  the 
steady state express very low levels of TSLPR that is up- 
regulated in the presence of TSLP (Reche et al., 2001). In-
deed, we found CD11c+TSLPR+ cells in the tumor (Fig. 4 A) 
and in draining but not in nondraining LNs (Fig. 4 B). These 
findings witness DC activation in vivo by a stimulus able to 
up-regulate the TSLPR. This evidence, along with the in vitro 
demonstration that CD80 expression by DCs conditioned by 
CAF supernatant depends on TSLP secretion (shown in 
Fig. 3 C), validates TSLP as the cytokine responsible for activa-
tion in the tumor of DCs with features of TSLP-treated DCs.
In our hypothesis, TSLP-conditioned DCs present in the 
draining LNs activate Th2 cells that then home to the tumor 
under the influence of Th2 attractant chemokines. Thus, we 
evaluated, by real-time PCR, mRNA expression of TARC/
CCL17 and MDC/CCL22 in tumor samples and found ex-
pression in the tumor but not in the corresponding surround-
ing tissue (Fig. 4 C). We then measured expression of the two 
cytokines in tumor epithelial and stromal cells collected by 
LCM and in cultured paired tumor cells and CAFs from the 
same patient (Fig. 4 D). We found expression of both cyto-
kines in the stroma (Fig. 4 D, top). In addition, MDC/CCL22, 
as already described in ovarian cancer (Curiel et al., 2004), 
was also expressed in tumor epithelial cells (Fig. 4 D, right).   
As for TNF (Fig. 2 E), TARC/CCL17 and MDC/CCL22 
expression in the stroma was not attributable to CAFs (Fig. 4 D, 
bottom) but, in agreement with our previous in vitro results 
(Fig. 3 D), was most likely attributable to inflammatory cells 
(e.g., DCs). Collectively, these results support our hypothesis 
that TSLP-conditioned DCs induced by CAF-secreted TSLP 
migrate to the draining LNs to prime Th2 cells that home to the 
tumor under the influence of Th2-attracting chemokines.
DISCUSSION
In this study, we first show that in pancreatic cancer the Th2 
immune deviation has an active role in tumor progression, in 
that the quantity of Th2 with respect to Th1 cells present   
in the tumor stroma has a direct correlation with prognosis in 
surgically  resected  patients. Although  tumor  antigen–specific 
CD4+ Th2 cells have been already described in the blood 
of patients with different neoplastic diseases (Tatsumi et al., 
2002, 2003; Slager et al., 2003; Marturano et al., 2008), to 
our knowledge this is the first demonstration of a statisti-
cally significant correlation between prevalent Th2 over 
Th1 tumor immune infiltrate and poor prognosis. Notably, 
statistical analysis proved that the ratio, rather than the   
absolute number, of GATA-3+ cells correlate with poor 
prognosis, pointing to the importance for the clinical out-
come of the balance between Th2 and Th1 cells present in the 
tumor microenvironment.
Second, we addressed what leads to the Th2 immune de-
viation in pancreatic cancer and identified a central role for 
Figure 4.  TSLP-conditioned DCs and Th2-attractant chemokines are 
present in vivo. (A and B) TSLP-conditioned DCs are present in the tumor 
and in draining but not in nondraining LNs. (A) Immunohistochemical analy-
sis for CD11c+TSLPR+ cells in the tumor representative of tumor samples 
from 10 patients. Bars, 100 µm. (B) FACS analysis of CD11c+TSLPR+CD14 
cells in draining (top) and corresponding nondraining (bottom) LNs repre-
sentative of paired samples from four patients. Open histograms represent 
TSLPR staining; filled histograms represent the isotype control. Num-
bers indicate the percentage of gated (left) and positive (right) cells.  
(C and D) TARC/CCL17 and MDC/CCL22 mRNA expression in tumor and the 
corresponding surrounding tissue (C; each dot and corresponding triangle 
represent surgical samples from single patients), in tumor epithelial and 
stromal cells collected by LCM (D, top; representative of tumor samples 
from three patients), and in isolated and in vitro–cultured paired tumor cell 
lines and CAFs from the same patient (D, bottom; representative of tumor 
samples from three patients). Data in C and D are means of at least dupli-
cate determinations ± SD. Responses significantly different are indicated as: 
*, P < 0.05 (determined by paired one-tailed Student’s t test).
CAFs, which, through TSLP secretion, activate mDCs with 
features of TSLP-conditioned DCs with Th2-polarizing ca-
pability.  Notably,  DCs  with  the  feature  of TSLP-activated 
DCs (i.e., CD11c+TSLPR+) were found in vivo in the tumor 
stroma and in draining, but not in nondraining, LNs.JEM VOL. 208, March 14, 2011 
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macrophages in pancreatic cancer has been reported (Kurahara 
et al., 2009), and we also have preliminary evidence of tumor 
stroma infiltration by CD68+CD163+ cells (unpublished data).
Clinical outcome in pancreatic cancer patients with re-
sectable tumor is still disappointing with a median survival of 
20–22 mo (Hidalgo, 2010). However, time to relapse and 
overall survival in this patient population may greatly vary, 
and few risk factors for recurrent disease have been defined so 
far (Hidalgo, 2010). In this paper, we identified the ratio of 
Th2/Th1 tumor-infiltrating lymphoid cells as an indepen-
dent prognostic marker of survival that might be used for pa-
tient stratification in future prospective studies.
Notably, elucidation of the cytokine/chemokine network 
implicated in the Th2 immune deviation may allow for the 
design  of  innovative  therapeutic  strategies  to  complement 
currently available therapies (including therapeutic vaccina-
tion or adoptive immunotherapy) for pancreatic cancer based 
on proinflammatory cytokines and TSLP blocking strategies. 
Toward the feasibility of these approaches, clinical trials of 
TNF antagonists in advanced cancer patients have resulted in 
disease stabilization and some partial responses (Harrison et al., 
2007; Mantovani et al., 2008). Clinical grade anti–IL-1 Abs 
are available to treat autoimmune and autoinflammatory dis-
eases (van den Berg, 2000; Atzeni and Sarzi-Puttini, 2009; 
Lachmann et al., 2009) and, recently, treatment with an IL-1 
inhibitor in patients with smoldering or indolent multiple 
myeloma at risk of progression to active myeloma was responsi-
ble for improved progression-free survival (Lust et al., 2009). 
Finally, concerning possible ways to silence TSLP, as a result of 
its role in allergy, several companies are already involved in devel-
oping clinical grade neutralizing Abs, which should be available 
for clinical applications in the near future (Edwards, 2008).
Future studies will address the mechanisms by which Th2 
cells promote tumor progression and, specifically, which cel-
lular and molecular interactions they use to do so within the 
tumor microenvironment. These studies will also possibly be 
conducted in animal models of spontaneous pancreatic can-
cer development recapitulating the different steps of pancre-
atic carcinogenesis from inception to invasive cancer paralleling 
the human disease (Hingorani et al., 2003; Leach, 2004). Further-
more, whether the mechanisms of Th2-mediated inflammation 
constitute a common phenomenon operative in multiple human 
tumors should also be investigated. Specifically, the role of 
TSLP and the ratio of G/T-infiltrating lymphocytes in other 
tumor types, either gastrointestinal or other epithelial tumors 
with important fibrotic component, should be addressed.
In summary, we identified in human pancreatic cancer a 
complex cross talk among tumor cells, CAFs, DCs, and T cells 
leading to Th2 inflammation, which significantly correlates 
with poor survival. Thus, therapeutic intervention aimed at 
interfering with this negative cross talk may prove to be ben-
eficial for improving prognosis in pancreatic cancer patients.
MATERIALS AND METHODS
Patient population enrolled for survival analysis. 69 patients who had R0 
or R1 resection of a stage IB-III pancreatic cancer, according to the 2002 stag-
ing criteria of the American Joint Commission on Cancer (Evans et al., 2002),   
Previous studies addressed the presence of DCs in pancre-
atic cancer (Dallal et al., 2002; Fukunaga et al., 2004) with 
somewhat conflicting results. DCs were identified by anti-
S100 staining in Fukunaga et al. (2004) and by anti-S100 and 
CD1a in Dallal et al. (2002). Dallal et al. (2002) found signifi-
cant numbers of S100+ or CD1a+ cells in a very small per-
centage of patients. Compared with this paper, Fukunaga 
et al. (2004) identified patients with different levels of im-
mune infiltration and found that infiltration of S100+ cells 
paralleled infiltration by CD4+ and CD8+ T cells. The DC 
marker used in our study is different from the ones previously 
used. Because CD11c expression is not limited to DCs, it is 
possible that neutrophils and monocytes, which are possibly 
present in the tumor stroma, might also have been stained.
Cancer-related inflammation has been proposed as the sev-
enth hallmark of cancer (Dunn et al., 2004; Grivennikov et al., 
2010), and recently proinflammatory CAFs from a trans-
genic mouse tumor model were shown to orchestrate tumor- 
promoting inflammation in a NF-B–dependent manner (Erez 
et al., 2010). In this scenario, our data identify a new molecule 
(i.e., TSLP) and a new function for CAFs in driving, under 
the influence of tumor cells, Th2-mediated inflammation that 
correlates with reduced survival in pancreatic cancer.
Collectively, based on our in vitro and in vivo data we 
propose a model of a complex cross talk among tumor cells, 
CAFs, Th2 cells, and possibly other immune cells favoring   
tumor promotion (Fig. S3). First, proinflammatory cytokines 
(TNF and IL-1) are released by pancreatic tumor cells and 
elicit the release of TSLP by CAFs (Fig. S3 A). Secretion of 
these cytokines by pancreatic tumor cells has been previously 
reported (Arlt et al., 2002; Müerköster et al., 2004; Egberts   
et al., 2008). However, it is still unknown which signals are driv-
ing their secretion. Endogenous factors released by dead and 
dying tumor cells or present in the tumor microenvironment 
might serve as endogenous stimuli for NF-kB and inflamma-
some activation required for proinflammatory cytokine acti-
vation and release (Tschopp and Schroder, 2010; Fig. S3 A). 
Second, TSLP released by activated CAFs induces activation/
maturation of tumor antigen–loaded resident DCs (Fig. S3,   
B and C). Third, activated DCs migrate to the draining LNs 
where they activate tumor antigen–specific CD4+ Th2 cells 
(Fig. S3 D). Fourth, CD4+ Th2 cells primed in the draining 
LNs home to the tumor under the influence of tumor- 
derived Th2 chemoattractants (TARC and MDC; Fig. S3 E). 
Fifth, recruited CD4+GATA-3+ Th2 cells may exert tumor-
promoting effector functions (Fig. S3 F). Indeed, an altered 
balance between Th2 and Th1 cytokines present in the tumor 
microenvironment might further contribute to fibrosis. It has 
been shown that fibrogenesis is strongly linked with develop-
ment of Th2 responses, and Th1 and Th2 cytokines exert op-
posing roles by promoting collagen degradation and synthesis, 
respectively (Wynn, 2004). Th2 cells might also promote differ-
entiation of M2 macrophages both directly by tumor antigen–
specific recognition of peptide–MHC class II complexes   
at the surface of differentiating monocytes and indirectly 
through Th2 cytokines release. The presence of M2-polarized 476 TSLP-driven Th2 polarization in pancreatic cancer | De Monte et al.
the following stimuli: 20 ng/ml TNF, 10 ng/ml IL-1, and supernatant from 
tumor cells. In inhibition experiments, 2 µg/ml anti-TNF, anti–IL-1, or 
isotype-matched Abs  (BD)  were  added. TSLP  release  was  quantified  by 
ELISA (R&D Systems).
Myeloid DC isolation and activation. Myeloid DCs were isolated from 
blood buffy coats of adult healthy donors after separation of mononuclear 
cells and enrichment in monocytes using density gradients as described in 
Recalde (1984). Monocytes were stained with anti-CD3, anti-CD19, anti-
CD16, anti-CD14, anti-CD56 fluorescein (FITC), CD4-PE, and CD11c-
APC–conjugated Abs. LineageCD4+CD11c+ cells were then isolated by 
sorting (MoFlo cell sorter; Beckman Coulter) with a purity of 97–99%. DCs 
were cultured at 106/ml in 96-well plates in 2% FBS IMDM with or without 
the following stimuli: 15 ng/ml TSLP (R&D Systems), 25 ng/ml poly I:C 
(Sigma-Aldrich), and supernatants of untreated or TNF-treated CAFs and HDFs. 
In inhibition experiments, 1 µg/ml anti-TSLP (R&D Systems) or 10 µg/ml 
anti-TNF (BD) Abs were added. After 24 h, DCs were washed and left for a 
further 48 h in culture. Cytokine and chemokines release in DC supernatants 
was measured by human chemokines and the inflammatory cytokines CBA 
(BD) or ELISA (TARC/CCL17 and MDC/CCL22; R&D Systems).
FACS analysis. DCs were stained with anti-CD80, anti-CD83, anti-HLA-DR, 
anti-CD86, and anti-CD40 Abs conjugated with either FITC or PE (BD) 
and anti-TSLPR, followed by biotinylated anti–mouse IgG, and then with 
streptavidin-PE  or  –PE-Cy5  (BioLegend).  Samples  were  acquired  with 
FACSCalibur (BD).
DC/T cell co-culture. Naive CD4+ T cells were purified from cord   
blood with anti-CD4–coated beads (Miltenyi Biotec), obtaining ≥90% 
CD4+CD45RA+ cells. Activated DCs were added to naive CD4+ T cells   
(5 × 104/well) at a 1:5 ratio in 96-well plates. After 6 d, supernatants were 
tested for IL-13 and IFN- release by ELISA (Mabtech).
Immunohistochemical analysis. Immunohistochemistry was performed 
on tissue sections from surgical specimens, as detailed in Tassi et al. (2008). 
The following Abs were used: anti–T-bet and anti–IL-1 (Santa Cruz Bio-
technology, Inc.), anti–GATA-3 (R&D Systems), anti-CD11c (Novocastra), 
and anti-TSLPR (BioLegend). For GATA-3 and T-bet evaluation, immuno-
stained slides were digitalized with the Aperio slide scanner and correspond-
ing tumor areas on adjacent sections were selected. Lymphocytes with nuclear 
staining were counted using the IHC Nuclear Image Analysis algorithm of 
the Spectrum Plus software (Aperio) and normalized to a 1-mm2 area. 
CD11c and TSLPR coexpression was visualized using a sequential immuno-
peroxidase labeling and erasing technique (Glass et al., 2009) with the alco-
hol-soluble peroxidase substrate 3-amino-9-ethylcarbazole, combined with 
an antibody-antigen elution after the first antibody reaction.
Statistical  analysis. The survival curves were estimated with univariate 
analyses according to the Kaplan-Meier method and compared using the 
log-rank test. Univariate and multivariate analyses by the Cox proportional 
hazard model were performed to estimate the independent potential risk 
factors that influence disease-free survival and overall survival. All the proba-
bility values were from two-sided tests. Analyses were performed using the 
Statistica 4.0 statistical package for Windows (Statsoft).
Online  supplemental  material.  Fig.  S1  shows  a  scatter  plot  analy-
sis of overall survival and G/T ratio. Fig. S2 shows the characteristics of 
cell lines used in the study. Fig. S3 depicts a model of cross talk among 
tumor cells, CAFs, and DCs driving Th2 inflammation in pancreatic can-
cer. Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20101876/DC1.
We thank M. Bellone, P. Dellabona, R. Pardi, V. Russo, and C. Traversari for helpful 
discussions and critical review of this manuscript; S. Grassi for helping with the 
LCM experiments; M. Alessio for providing reagents for Western blot analyses;  
followed  by  different  chemotherapeutic  regimens  and  radiotherapy,  were   
enrolled in the survival study. The characteristics of the patients are reported 
in Table I.
Tissue specimens and establishment of cell lines. Tumor and LN 
samples were collected at surgery. Surrounding tissue was sampled at least at 
a 1-cm distance from macroscopically evident neoplastic tissue. However, 
morphological characteristics varied among samples from conserved normal 
parenchyma  to  preexisting  or  associated  obstructive  pancreatitis.  Normal 
pancreatic tissue was obtained from surgical samples of patients who under-
went surgery for benign pancreatic lesions. The Institutional Ethics Commit-
tee (Comitato Etico Fondazione Centro San Raffaele del Monte Tabor, 
Istituto Scientifico Ospedale San Raffaele) had approved the study protocol, 
and written informed consent was obtained from all donors. Tumor speci-
mens were in part frozen for RNA extraction and in part used for cell cul-
ture. Tumor pieces were cultured in IMDM medium (Lonza) plus 10% FBS, 
and after a few passages tumor cells and CAFs were separated with anti-fibro-
blast Ab-coated beads (Miltenyi Biotec). Draining and nondraining LNs were 
mashed in 2% FBS RPMI, 10 mM Hepes, and 400 U/ml collagenase D 
(Sigma-Aldrich).
Western  blotting.  Expression  of    smooth  muscle  actin  (SMA),  pan- 
cytokeratin, and p53 by cultured CAFs and tumor cells was evaluated by Western 
blotting, as described in De Monte et al. (2008). Abs used were mouse anti-
pan cytokeratin (Sigma-Aldrich), rabbit polyclonal anti–-SMA (Abcam), 
mouse anti-p53 (DAKO), and mouse anti–-actin (Sigma-Aldrich), followed 
by goat anti–mouse HRP or swine anti–rabbit HRP (DAKO), respectively. 
Immunodetection was performed by enhanced chemiluminescence (GE 
Healthcare), followed by autoradiography on Biomax films (Kodak).
Detection of K-ras mutations. Genomic DNA was extracted from 2 × 106 
pancreatic cancer cells or CAFs with the QIAamp DNA mini kit (QIAGEN), 
and 30 ng of each sample was amplified for 40 cycles (58°C annealing tem-
perature) with PFU-Turbo DNA polymerase (Agilent Technologies) with 
the following primers: Kras forward, 5-GGTGGAGTATTTGATAGTG-
TATTAAACC-3;  Kras  reverse,  5-TCATGAAAATGGTCAGAGA-
AACC-3. 283-bp PCR products containing k-ras codon 12 and 13 purified 
with QIAquick kit (QIAGEN) were then sequenced on both strands and 
analyzed with the FinchTv software (Geospiza).
LCM. Epithelial and stromal tumor cells were collected from frozen samples 
using the Arcturus LCM system, according to the manufacturer’s instructions. 
The two tumor components, identified under microscopy, were cut and 
transferred on capsure HS caps and total RNA was extracted as described in 
the next section.
Real-time PCR. Total RNA was extracted using the PicoPure RNA isola-
tion kit (Arcturus) or the RiboPure kit (Ambion), according to the manufac-
turers’ instructions. 1 µg RNA was retro-transcribed with the High-Capacity 
cDNA reverse transcription kit (Applied Biosystems), and 10–50 ng cDNA 
was used for real-time PCR. To analyze the expression of different genes 
from RNA obtained by LCM a preamplification step was performed, accord-
ing to the manufacturers’ instructions. Assays on demand specific for human 
TSLP  (Hs00263639-m1),  IL-1  (Hs00174097-m1), TNF  (Hs00174128), 
TARC/CCL17 (Hs00171074-m1), MDC/CCL22 (Hs99999075-m1), and 
GAPDH (Hs99999905-m1; Applied Biosystems) were used. Real-time PCR 
was performed on an AB7900HT machine (Applied Biosystems) using the 
S.D.S2.1 program for the analysis. Fold induction among samples was calcu-
lated by 2Ct method. The target gene values were normalized with 
GAPDH values.
Fibroblasts stimulation and TSLP quantification. Fibroblasts were cul-
tured overnight at 150.000–300.000 cells/ml in IMDM with 10% FBS, fol-
lowed by 5–8 h of starving without serum. Medium was then replaced with 
IMDM with 2% FBS, and fibroblasts were cultured for 48 h with or without JEM VOL. 208, March 14, 2011 
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